Brief: Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth STARLIGHT-1 Trial Site
14/10/2026 22:34
BRIEF-Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth STARLIGHT-1 Trial Site Oct 14 (Reuters) - Estrella Immunopharma Inc ESLA.O:
ESTRELLA IMMUNOPHARMA ACTIVATES INTERMOUNTAIN HEALTH LDS HOSPITAL AS FIFTH CLINICAL SITE FOR PHASE I/II STARLIGHT-1 TRIAL IN B-CELL NON-HODGKIN’S LYMPHOMA
Source text: ID:nBw6knkbBa
Further company coverage: ESLA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Estrella Immunopharma
See all newsNASDAQ RESUMED AT 03:10 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:05 PM
Brief: Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth STARLIGHT-1 Trial Site
Brief: Estrella Immunopharma Announces $8.0 Million Registered Direct Offering
Brief: Estrella Immunopharma Offers Up To 2.5 Mln Shares For Resale By Selling Stockholders